Omega-3 Fatty Acids for Major Depressive Disorder During Pregnancy

Omega-3 Polyunsaturated Fatty Acids in Women With Major Depressive Disorders During Pregnancy

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00618865

Enrollment

Registered

2008-02-20

Start date

2004-06-30

Completion date

2004-06-30

Last updated

2008-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depressive Disorder

Keywords

Omega-3 Fatty Acids, Major Depressive Disorder, Pregnancy, Women during pregnancy and after childbirth are more vulnerable to psychiatric disorders, Pharmacotherapy for depression during pregnancy is a clinical dilemma., Omega-3 polyunsaturated fatty acids (PUFAs) might be a promising alternative of treatment for pregnant women with depression.

Brief summary

Whether high-dose omega-3 fatty acids supplement would be an effective treatment in patients with major depressive disorder during pregnancy and breast-feeding.

Interventions

DIETARY_SUPPLEMENTOmega-3 fatty acids

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

18 Years to 40 Years

Healthy volunteers

Inclusion criteria

* Eligible participants were pregnant women, aged 18 to 40 years, with major depressive disorder onset between their 16th week (second trimester) and 32nd week (third trimester) of gestation at the Department of Obstetrics.

Exclusion criteria

* Subjects were excluded with a DSM-IV diagnosis of bipolar disorders, psychotic disorders, substance abuse or dependence for at least 3 months, or any Axis-II diagnosis of borderline or antisocial personality disorder.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 5, 2026